Live feed21:56:00·739dPRReleasevia QuantisnowImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder CancerByQuantisnow·Wall Street's wire, on your screen.IBRX· ImmunityBio Inc.Health Care
